Amylgen’s Articles & Posters

2015/01/08

Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy.

Authors: Ilya Chumakov1, Serguei Nabirotchkin1, Nathalie Cholet1, Aude Milet1, Aurélie Boucard1, Damien Toulorge1, Yannick Pereira1, Esther Graudens1, Sory Traoré1, Julie Foucquier1, Mickael Guedj1, Emmanuel Vial1, Noëlle […]
2015/01/01

Brain Toxicity and Inflammation Induced In Vivo in Mice by the Amyloid-β Forty-Two Inducer Aftin-4, a Roscovitine Derivative

  Authors: Meunier J1, Borjini N1, Gillis C1, Villard V1, Maurice T2. 1Amylgen, Montferrier-sur-Lez, France. 2Amylgen, Montferrier-sur-Lez, France INSERM U. 710, University of Montpellier 2, Montpellier, France. […]
2014/01/31

Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ25-35 peptide-induced toxicity in vitro and in vivo in mice.

  Authors: El Bitar F1, Meunier J, Villard V, Alméras M, Krishnan K, Covey DF, Maurice T, Akwa Y.   Abstract: Rational > Pregnenolone sulfate (PREGS) […]
2013/11/27

Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer’s disease.

  Authors: Maurice T, Mustafa MH, Desrumaux C, Keller E, Naert G de la C García-Barceló M, Rodríguez Cruz Y, Garcia Rodríguez JC.   Abstract : […]